Ibrutinib outperforms FCR in CLL
- PMID: 31417194
- DOI: 10.1038/s41571-019-0265-6
Ibrutinib outperforms FCR in CLL
Comment on
-
Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia.N Engl J Med. 2019 Aug 1;381(5):432-443. doi: 10.1056/NEJMoa1817073. N Engl J Med. 2019. PMID: 31365801 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources